Alzinova AB is a privately held Swedish biotechnology enterprise engaged in drug discovery research for Alzheimer’s disease. A platform technology based on the AβCC peptides™ provides the company with long-term R&D capabilities. This technology enables Alzinova to explore novel therapeutic strategies and develop research tools that enhance productivity within Alzheimer's disease research.Read more »
Non-fibrillogenic mimics of endogenous toxic amyloid-β aggregates ('oligomers') are developed by Alzinova as vaccines with high efficacy, and non-toxic mimetic amyloid-β as replacement therapy. The unique properties of the AβCC peptide™ technology has also enabled the development of a monoclonal antibody with 100% specificity for the disease-driving oligomers.
Professor Torleif Härd (Swedish University of Agricultural Sciences) and co-workers have published a structural model of AβCC protofibrils in… Read more »
Anders Sandberg, COO, will be attending BIO-Europe in Frankfurt, November 3-5. BIO-Europe is the largest… Read more »
The new 2014 Alzheimer’s Association Facts and Figures inlcudes a special report on the toll that… Read more »